How many people of COVID-19 Vaccine have played recombinant COVID-19 Vaccine

How many people of COVID-19 Vaccine played

at the press conference of the joint prevention and control mechanism of the State Council, it was announced that COVID-19 Vaccine had been inoculated more than 200 million times in total across the country, and Sinopharm China Biological COVID-19 Inactivated Vaccine had been inoculated more than 100 million times in China, which is the largest domestic vaccination volume and the most safe COVID-19 Vaccine widely used in the world! COVID-19 vaccination has been widely carried out throughout the country. As the main force in the research, development and production of COVID-19 vaccine in China, Sinopharm Group Biotech, a central enterprise, recently released the latest blockbuster data of COVID-19 inactivated vaccine!

The overall adverse reaction rate is low and has good safety

The Chinese Journal of Epidemiology, a core academic journal in China, published a paper entitled "Safety evaluation of large-scale emergency use of novel coronavirus inactivated vaccine (Vero cell)", which was based on the safety evaluation of large-scale emergency use of novel coronavirus inactivated vaccine by Sinopharm Beijing Institute of Biological Products and Wuhan Institute of Biological Products. Research has shown that after emergency use of large-scale inactivated COVID-19 vaccines (Vero cells), the incidence of general reactions is low, and no serious adverse reactions have been observed. The vaccine has good safety.

The results of Phase I/II clinical phased studies of COVID-19 Vaccine by Beijing Institute of Biological Products and Wuhan Institute of Biological Products of Sinopharm Group show that COVID-19 Inactivated Vaccine is safe after vaccination, without serious adverse reactions. 28 days after two doses of vaccine inoculation, the 4-fold growth rate of neutralizing antibody against COVID-19 was close to 100%.

Recombinant COVID-19 Vaccine Shangxin

Recombinant COVID-19 Vaccine of China Institute of Biology of Sinopharm Group was approved by the State Drug Administration for clinical trials. This is the third COVID-19 vaccine of China's biology after the two COVID-19 inactivated vaccines of Sinopharm Group China Biotech were approved for clinical use, becoming the third COVID-19 vaccine of China's biology.

Recombinant COVID-19 vaccine is a vaccine based on the natural structural characteristics of receptor binding region (RBD) of spike protein (S protein) of COVID-19, which is independently designed and developed by using structural biology and computational biology, and uses genetic engineering technology to construct engineering cell lines and recombine antigen proteins. It has clear targets and strong pertinence. After immunization, the body can be induced to produce targeted neutralizing antibodies, thereby blocking the binding of the virus to receptor cells and exerting a protective effect.

The receptor binding region (RBD) of spike protein (S protein) of COVID-19 binds to the cell surface receptor ACE2 and invades human cells.

This vaccine is designed for all age groups, and the current design allows vaccination for all age groups aged 3 and above. The technology route for recombinant protein vaccines is mature and suitable for large-scale production. The entire preparation process does not involve live viruses or other infectious materials, and does not require high-level biosafety environments. Therefore, it is entirely possible to achieve simultaneous market approval and mass production. Because it does not require high-level biosafety facilities for production, it is very advantageous for large-scale cultivation and production.

Which company produced the recombinant COVID-19 vaccine

The recombinant subunit vaccine of COVID-19 currently used in our province is the recombinant COVID-19 vaccine (CHO cell) produced by Anhui Zhifeilong Kema Biological Pharmaceutical Co., Ltd. (Zhifeilong Kema). The principle is to recombine the receptor binding region (RBD) gene of S protein of COVID-19 into the gene of Chinese hamster ovary (CHO) cells, express it in vitro to form RBD dimer, and add aluminum hydroxide adjuvant to improve immunogenicity.

COVID-19 recombinant protein vaccine was expressed in CHO cells. This cell has been used in hepatitis B vaccine for many years, and is also widely used in the field of bioengineering.

What is the recombinant COVID-19 vaccine

The recombinant neocoronal vaccine refers to the application of a weakened version of the viral gene in an adenovirus to prevent diseases caused by novel coronavirus infection. The recombinant novel coronavirus vaccine has the characteristics of high safety and good stability, and is now in the clinical trial stage. If the research and development is successful, this recombinant novel coronavirus vaccine will begin to be used in large doses in clinical practice, which can prevent novel coronavirus infection. Novel coronavirus is a low virulence and highly infectious virus, so protective measures must be taken at ordinary times.